Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

Clinical trial NCT05741164 · RECRUITING

Trial details

NCT number: NCT05741164
Sponsor: Emory University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Triple-Negative Breast Carcinoma Refractory Triple-Negative Breast Carcinoma Unresectable Triple-Negative Breast Carcinoma

Start date: 2024-09-01
Primary completion: 2028-06-30
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.